BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/18/2016 3:13:00 PM | Browse: 1418 | Download: 3183
Publication Name World Journal of Gastroenterology
Manuscript ID 29489
Country United States
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Observational Study
Article Title Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country
Manuscript Source Unsolicited Manuscript
All Author List Naomi Khaing Than Hlaing, Debolina Banerjee, Robert Mitrani, Soe Htet Arker, Kyaw San Win, Nyan Lin Tun, Zaw Thant, Khin Maung Win and K Rajender Reddy
Funding Agency and Grant Number
Corresponding Author K Rajender Reddy, MD, Ruimy Family President’s Distinguished Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology, Director of the Viral Hepatitis Center, and Medical Director of Liver Transplantation, Division of Gastroenterology and Hepatology, University of Pennsylvania, 2 Dulles, 3400 Spruce Street, Philadelphia, PA 19104, United States. rajender.reddy@uphs.upenn.edu
Key Words Hepatitis C virus; Pegylated-interferon; Ribavirin; Sustained virologic response; Rapid virologic response
Core Tip peg-interferon (peg-IFN) and ribavirin (RBV) therapy was a viable treatment option for hepatitis C virus (HCV)-infected patients in Myanmar due to its availability and affordability. Currently, direct-acting antiviral agents are not widely accessible to the Myanmar population. Therefore, HCV treatment is still being conducted with peg-IFN and RBV therapy. This treatment regimen was shown to be reasonably efficacious with minimal adverse events. Fibrosis scores, baseline albumin, HCV RNA levels and rapid virologic response all independently predicted sustained virologic response.
Publish Date 2016-11-18 15:13
Citation Hlaing NKT, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR. hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country. World J Gastroenterol 2016; 22(43): 9613-9622
URL http://www.wjgnet.com/1007-9327/full/v22/i43/9613.htm
DOI http://dx.doi.org/10.3748/wjg.v22.i43.9613
Full Article (PDF) WJG-22-9613.pdf
Full Article (Word) WJG-22-9613.doc